医学文献 >>
  • 检索发现
  • 增强检索
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
默认
×
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): A randomised, controlled, phase 3 trial

广告
第一作者: Buzdar,A.U.
作者: Buzdar,A.U. [1] ; Suman,V.J. [2] ; Meric-Bernstam,F. [3] ; Leitch,A.M. [4] ; Ellis,M.J. [5] ; Boughey,J.C. [6] ; Unzeitig,G. [7] ; Royce,M. [8] ; McCall,L.M. [9] ; Ewer,M.S. [10] ; Hunt,K.K.
作者单位: Doctors Hospital of Laredo, Laredo, TX, United States [1] Department of Medical Affairs, University of Texas MD Anderson Cancer Center, Houston, TX, United [2] Office of Vice President for Clinical Research, University of Texas MD Anderson Cancer Center [3] Division of Medical Oncology, Washington University School of Medicine, St Louis, MO, United States [4] Department of Health Sciences Research, Mayo Clinic, Rochester, MD, United States [5] Department of Internal Medicine, University of New Mexico Cancer Center, Albuquerque, NM, United [6] Department of Surgery University of Texas Southwestern Medical Center at Dallas, Dallas, TX, United [7] Department of Surgery, Mayo Clinic, Rochester, MD, United States [8] Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United [9] Alliance Statistics Center, Duke University Cancer Institute, Durham, NC, United States [10]
发布时间 2014-03-18
提交
  • 浏览0
The lancet oncology

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

法律状态公告日 法律状态 法律状态信息

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new医文AI 翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷